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CartilageAberrant ﬁbroblast growth factor (FGF) signaling disturbs chondrocyte differentiation in skeletal dysplasia, but
the mechanisms underlying this process remain unclear. Recently, FGF was found to activate canonical WNT/
β-catenin pathway in chondrocytes via Erk MAP kinase-mediated phosphorylation of WNT co-receptor Lrp6.
Here, we explore the cellular consequences of such a signaling interaction. WNT enhanced the FGF-mediated
suppression of chondrocyte differentiation in mouse limb bud micromass and limb organ cultures, leading to
inhibition of cartilage nodule formation in micromass cultures, and suppression of growth in cultured limbs.
Simultaneous activation of the FGF and WNT/β-catenin pathways resulted in loss of chondrocyte extracellular
matrix, expression of genes typical for mineralized tissues and alteration of cellular shape. WNT enhanced the
FGF-mediated downregulation of chondrocyte proteoglycan and collagen extracellular matrix via inhibition of
matrix synthesis and induction of proteinases involved in matrix degradation. Expression of genes regulating
RhoA GTPase pathway was induced by FGF in cooperation with WNT, and inhibition of the RhoA signaling
rescued the FGF/WNT-mediated changes in chondrocyte cellular shape. Our results suggest that aberrant FGF
signaling cooperates with WNT/β-catenin in suppression of chondrocyte differentiation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Endochondral ossiﬁcation, in which bone replaces pre-existing
cartilage, is the predominant mechanism of longitudinal bone growth.
Bones grow longer at the epiphyseal growth plates,where chondrocytes
progress through a series of differentiation stages. Chondrocytes leave
their resting state, proliferate in columns, exit the cell cycle and undergo
hypertrophy, during which they mineralize their matrix and undergo
apoptosis. The cartilage is then replaced by bone [1]. FGF signalingulty of Medicine, Room A3/246,
epublic. Tel.: +420 549495395.represents one of the major regulators of this process. Removal of
FGF-receptor 3 (FGFR3) leads to skeletal overgrowth inmice [2], where-
as activating mutations in FGFR3 account for several skeletal dysplasias
in humans, e.g., achondroplasia (ACH), which is the most prevalent
short-limbed dwarﬁsm, and thanatophoric dysplasia (TD),which repre-
sents the most common lethal skeletal dysplasia [3].
One of the hallmark features of FGFR3-related skeletal dysplasia is
profound disruption of the growth plate architecture, which, in TD,
leads to small or non-existing columns of hypertrophic chondrocytes
[4]. This demonstrates the negative effect of aberrant FGF signaling on
chondrocyte differentiation, although the mechanisms underlying this
phenotype remain unclear. One explanation for this may be FGFR3 in-
terference with indian hedgehog (Ihh)/parathyroid hormone-related
840 M. Buchtova et al. / Biochimica et Biophysica Acta 1852 (2015) 839–850
841M. Buchtova et al. / Biochimica et Biophysica Acta 1852 (2015) 839–850protein (PTHrP) signaling, which is necessary for proper chondrocyte
transition from the proliferating to hypertrophic stage [5]. The growth
plates of mouse models to both ACH and TD show inhibition of expres-
sion of components of Ihh and PTHrP signaling, whereas addition of
PTHrP to cultured chondrocytes partially counteracts the cellular
phenotypes regulated by FGFR3 [6–9]. In our opinion, impaired Ihh/
PTHrP signaling does not account for the full spectrum of chondrocyte
differentiation defects observed in TD. Other mechanisms yet to be
characterized are likely to mediate the FGFR3 effect on chondrocyte
differentiation, hampering our full understanding of the FGFR3 function
in bone growth.
Recently, we described the activation of the canonical (i.e., dependent
on β-catenin)WNT pathway by FGF signaling in chondrocytes, manifest-
ed by FGF-mediated β-catenin stabilization, its increased nuclear
accumulation and activation of β-catenin-dependent transcription. This
phenotype depends on Erk MAP kinase-mediated phosphorylation of
theWNT co-receptor Lrp6 on four conserved intracellular PPPS/TPmotifs
essential for WNT/β-catenin signal transduction [10,11]. Moreover,
FGFR3 mutations associated with skeletal dysplasia exhibit increased
signaling via the Erk/Lrp6 pathway [12]. Interestingly, canonical WNT li-
gands are present in growth plate cartilage, and physiological activation
of the WNT/β-catenin pathway promotes chondrocyte differentiation
therein, via inhibition of PTHrP signaling and induction ofmarkers typical
for terminally differentiated chondrocytes [12–14]. The present study
was undertaken to explore the effect of FGF andWNT/β-catenin signaling
interaction on regulation of chondrocyte differentiation.
2. Results and discussion
2.1. FGF activates WNT/β-catenin signaling in chondrocytes
Rat chondrosarcoma chondrocytes (RCS) are an immortalized,
phenotypically stable cell line that expresses FGFR2 and FGFR3 but not
FGFR1 or FGFR4, and produces abundant cartilage-like extracellularma-
trix (ECM) composed of sulfated proteoglycans and collagen type 2
[15–17]. Activation of FGFR signaling in RCS cells, by addition of exoge-
nous FGF2, resulted in Lrp6 phosphorylation at Ser1490 and Thr1572
(Fig. 1A) [10] accompanied by β-catenin accumulation persisting for
up to 5 days (Fig. 1B). We examined two additional models of cartilage
development for FGF2-mediated Lrp6 phosphorylation, i.e., primary
cultures of E12 mouse limb bud mesenchymal cells, induced to chon-
drocyte differentiation via micromass culture [18,19], and limb organ
cultures of mouse femurs isolated from E17.5 embryos. Both models
responded to FGF2 treatment with Lrp6 phosphorylation (Fig. 1A).
Ser1490 and Thr1572 belong to PPPS/TP motifs on Lrp6 which serve as
docking sites that sequester Axin1 and GSK3 from the β-catenin
destruction complex, allowing for β-catenin stabilization and transcrip-
tional activation [20]. Removal of PPPS/TP motifs impairs WNT signal-
ing, whereas phosphorylation within the PPPS/TP motifs by kinases
independent of the WNT/β-catenin pathway, such as Erk MAP kinase,
promotes WNT signaling [21,22]. In RCS chondrocytes, FGF2-mediated
Lrp6 phosphorylation enhanced the molecular response to WNT3a
(canonical WNT ligand) by more than 100 times [10].
To identify possible effectors underlying the FGF2 and WNT3a sig-
naling interaction, we used multiple luciferase reporters to determine
the FGF2 and WNT3a inﬂuence on the transcriptional activity of key
signaling pathways known to regulate chondrocyte behavior, such asFig. 1. FGF2 signaling activatesWNT/β-catenin signaling in chondrocytes. (A) RCS chondrocytes
typemouse embryos at E17.5 were treatedwith FGF2 and analyzed for Lrp6 phosphorylation at
(B) RCS chondrocyteswere treatedwith FGF2 (10 ng/ml) for up to 5 days and analyzed for total
for the entire duration of the FGF2 treatment. (C) RCS chondrocytes were transfected with the g
(R-Luc) vectors, grown for 24 h, treated with FGF2 (ng/ml) andWNT3a (40 ng/ml) for 20 h an
fections (eachmeasured twice), with indicated standard deviations. Statistically signiﬁcant diffe
of three or four (pGL3-E-cadherin, pTL-ELK1-Luc) experiments. Treatment with TGFβ2 (10 ng/m
Note the strong Topﬂash activation (red square) mediated by FGF2/WNT3a (logarithmic scale fNF-κB, Snail, Elk1 (a reporter for Erk MAP kinase activity), Sox9,
Tgfβ and Ihh [11,23–27]. FGF2 and WNT3a modulated the activity
of all tested reporters (Fig. 1C). However, these changes were
minor compared to the massive β-catenin transcriptional activation
(Topﬂash reporter) induced by FGF2 and WNT3a co-stimulation,
suggesting that β-catenin is a major effector of the FGF and WNT
signaling interaction.
2.2. FGF2 andWNT3a act in synergy in suppression of chondrocyte differen-
tiation in mouse limb bud micromass cultures and limb organ cultures
Having established that FGF andWNT/β-catenin signaling interact in
RCS chondrocytes, we explored the effects of FGF2 and WNT3a
treatment on mesenchymal micromass cultures isolated from E12
mouse limb buds. This model recapitulates chondrocyte differentiation
in vitro, with formation of cartilage nodules observable at 7 days of
culture and ECM mineralization detectable at 14 days [28] (Fig. 2A, B).
The matrix mineralization observed in the micromass cultures grown
for 14 days may have originated from osteoblast differentiation of
mesenchymal cells, or from hypertrophic chondrocyte differentiation.
As mineralization took place outside but not inside the cartilaginous
nodules, it is likely that the mineralized matrix was deposited by
newly differentiated osteoblasts rather than hypertrophic chondrocytes
(Fig. 2B, right panel). This was conﬁrmed by the quantitative RT-PCR
analysis of markers speciﬁc to proliferating chondrocytes (Collagen
type 2), hypertrophic chondrocytes (Collagen type 10) and osteoblasts
(Runx2, Osteocalcin), which demonstrated partial decrease of chondro-
cyte markers at day 14, accompanied by massive upregulation of
Runx2 and Osteocalcinmessages (Fig. S1).
When used alone, both FGF2 and WNT3a suppressed chondrocyte
differentiation in the micromass cultures, as evidenced by a reduction
in both the number and size of the chondrocytic nodules developed
after 7 days. This phenotype was most pronounced in cells treated si-
multaneously with both FGF2 and WNT3a (Fig. 2A). In contrast, FGF2
and WNT3a increased matrix mineralization at 14 days of culture,
with the strongest effect observed in cultures treated with both growth
factors together (Fig. 2B). Thus, FGF appeared to act in synergy with
WNT/β-catenin signaling in inhibiting chondrocyte differentiation
while enhancing osteoblast differentiation in the micromass cultures
(Fig. 2C).
Similar to RCS chondrocytes or limb bud micromass cultures, FGF2
triggered Lrp6 phosphorylation in freshly isolated E17.5 mouse femurs
(Fig. 1A). We used limb organ cultures to test whether FGF and WNT/
β-catenin signaling cross-talk affected chondrocyte behavior in the
growth plate cartilage. Tibias isolated from E18 mouse embryos
exhibited normal growth plate architecture, with distinct zones of
proliferating and differentiating chondrocytes, including terminally
differentiated chondrocytes at the chondro-osseous junction (data not
shown). Treatment of such tibias with FGF2 for 8 days resulted in
growth plates that were signiﬁcantly shorter compared to controls
and had a markedly disorganized architecture, as manifested by a
reduced hypertrophic zone with absence of columnar chondrocytes
(Fig. 3A, B). This was conﬁrmed by a reduction of the Collagen type 10
expression in tibias treated with FGF2 (Fig. 3C). Tibias treated with
WNT3a alone grew normally, in contrast to tibias treated with FGF2/
WNT3a, which exhibited themost profound growth inhibition accompa-
nied by virtual elimination of Collagen type 10 expressing chondrocytes., micromass cultures isolated fromE12mouse hindlimb or femurs dissected out fromwild-
Thr1572 or Ser1490 byWB (pLrp6). Levels of total Lrp6 and actin served as loading controls.
β-catenin byWB (quantiﬁedbydensitometry). Note thatβ-catenin accumulation persisted
iven pathway-speciﬁc ﬁreﬂy luciferase reporter (F-Luc) and control Renilla luciferase
d analyzed for luciferase activity. The data represent the average from at least three trans-
rences are indicated (Student's t-test; *p b 0.05; **p b 0.001). The results are representative
l) served as a positive control for TGF/BMP (pBV-SBE4-Luc reporter) signaling activation.
or the y-axis) compared to the rather minor changes in the activities of other reporters.
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Fig. 3. FGF2 andWNT3a inhibit growth inmouse limb organ culture. (A)Mouse tibias isolated fromE18 embryoswere cultured inmedia supplemented by FGF2 (50ng/ml) and/orWNT3a
(40 ng/ml) for 8 days. Four biological replicates are shown for each treatment. The length of each tibia was measured after the extraction from the embryo and after 8 days of incubation.
The graph shows differences between both time points (Δ length) (B). Statistically signiﬁcant differences are highlighted (ANOVA, *p b 0.05; **p b 0.001). Note that FGF2-mediated growth
inhibition was potentiated byWNT3a. The results are representative of three independent experiments. (C) Histological sections of representative tibias were stained with hematoxylin/
eosin (HE). Note the marked reduction of hypertrophic cartilage (H) in tibias treated with FGF2 and FGF2/WNT3a, with corresponding loss of Collagen type 10 expression (bottom panel,
Collagen type 10 in situ hybridization counterstained with eosin). Cj, chondro-osseous junction.
843M. Buchtova et al. / Biochimica et Biophysica Acta 1852 (2015) 839–850No similar effect on FGF2-mediated growth inhibitionwas found in tibias
treated by non-canonical (i.e., β-catenin independent) WNT ligand
WNT5a (Fig. S2). This demonstrates, along with the published literature
[29], that FGF signaling interferes with hypertrophic chondrocyte differ-
entiation in the growth plate. Activation of the WNT/β-catenin pathway
by treatment with WNT3a augmented this effect.Fig. 2. FGF2 andWNT3a alter chondrocyte differentiation inmouse limbmicromass cultures. (A
and/orWNT3a (10ng/ml) for 7 days. (B) Alizarin red staining ofmicromass grown for 14 days. T
(C) Graphs showing levels of alcian blue staining of the cartilage matrix (A) or alizarin red stain
independent biological replicates. Statistically signiﬁcant differences are highlighted (ANOVA,
Note the decrease in amounts and size of cartilage nodules in FGF2 andWNT3a treated cultures,
of both FGF2 and WNT3a on the matrix mineralization, which was most pronounced in culture2.3. FGF2 andWNT3a cooperate in regulation of chondrocyte cellular shape
and ECM turnover
In RCS chondrocytes, FGFR activation leads to rapid loss of chondro-
cyte sulfated proteoglycan ECM via inhibition of matrix synthesis and
active proteolytic degradation [30,31]. As evidenced by alcian blue) Alcian blue staining ofmouse hindlimbmicromass culture treatedwith FGF2 (10 ng/ml)
hewhite area in the right panel represents the signal used for quantiﬁcation. Bar— 500 μm.
ing of the calciﬁedmatrix (B). The data represent the average± standard deviation of four
*p b 0.05; **p b 0.001). The results are representative of three independent experiments.
with the strongest effect in cultures treatedwith FGF2/WNT3a. Also note thepositive effect
s treated with FGF2/WNT3a.
Fig. 4. FGF2 andWNT3a suppress ECM production in RCS chondrocytes. (A) Cells were treated with FGF2 (10 ng/ml) andWNT3a (50 ng/ml), stained with alcian blue to visualize the sul-
fated proteoglycan ECM and photographed (dark ﬁeld with contrast, 200x). (B) To quantify matrix production, cells were treated with FGF2 (10 ng/ml) and WNT3a (50 ng/ml) in the
presence of [35S]sulfate for 72 h and the amount of incorporated radioactivity was determined by liquid scintillation. The data represent the average from four wells, with the indicated
standard deviations (Student's t-test; *p b 0.001). Treatmentwith non-canonicalWNT5a (50 ng/ml) served as a negative control. (C) RCS chondrocyteswere treatedwith FGF2 (10 ng/ml)
andWNT3a (40 ng/ml) for 48 h and analyzed for collagen type 2 expression byWB.Note the negative FGF2-mediated effect on collagen type 2 quantity,whichwas further downregulated
by concomitant WNT3a treatment (quantiﬁed by densitometry). Actin served as loading control.
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WNT3a; WNT3a alone did not alter ECM production (Fig. 4A). This
was conﬁrmed by metabolic proteoglycan labeling with [35S]sulfate
used to quantify the amounts of sulfated proteoglycan ECM [30]
(Fig. 4B). Apart from proteoglycan ECM, the production of collagen
ECM was also downregulated by FGF signaling, as evidenced by
decreased expression of collagen type 2 following FGF2 treatment;
this effectwas enhanced byWNT3a, resulting in a lack of detectable col-
lagen type 2 expression in cells treated with FGF2/WNT3a for 72 h
(Fig. 4C).
Alteration of chondrocyte cellular shape is a key histological feature
of FGFR3-related skeletal dysplasia [4]. In RCS chondrocytes, a similar
phenotypewasmanifested as cell enlargement and ﬂattening following
treatment with FGF2, accompanied by cytoskeletal remodeling, illus-
trated here by phalloidin staining of the actin stress ﬁbers (Fig. 5A, D).
A subjective increase in substrate adhesion was also observed in
chondrocytes treated with FGF2, shown by vinculin staining of focal
adhesions (Fig. 5C). Although WNT3a had no effect on RCS cellular
shape when used alone, it enhanced the changes mediated by FGF2,
i.e., caused elongation along a single axis when compared to cells treat-
ed with FGF2 alone, which spread uniformly in all directions (Fig. 5A)
(Supplementary movie 1). We quantiﬁed these changes by measuring
the cell perimeter, which increases with cell size and complexity of
the cell boundary. The data presented in Fig. 5B demonstrates ~1 foldperimeter increase in cells treated with FGF2 and FGF2/WNT3a when
compared to untreated cells. Differences in cell shape were quantiﬁed
by determining the extend of cell “eccentricity”, reﬂecting elongation
along one axis. FGF2 increased cell eccentricity and this phenotype
was signiﬁcantly enhanced by WNT3a, while no changes in cell shape
were found in cells treated with WNT3 alone or in cells treated with
WNT5a alone or in combination with FGF2 (data not shown).
To identify genes involved in cellular phenotypes regulated by FGF2
and WNT3a, we carried out expression proﬁling in RCS chondrocytes
treated with FGF2 and/or WNT3a for 16 or 48 h, taking into account
that FGF2/WNT3a-mediated changes on ECM and cellular shape re-
quired at least 48 h to fully manifest [30] (Supplementary movie 1).
Gene expression proﬁling showed that WNT3a enhanced the FGF2
inhibitory effect on expression of several key components of the
ECM (Collagen type 2, Collagen type 9, Aggrecan, Chondroitin sulfate
proteoglycan 4, Cartilage immediate layer protein, Chondroadherin),
as well as proteins involved in proteoglycan production, such
as chondroitin sulfate synthase 3 (Table 1). In addition, WNT3a en-
hanced the FGF2-mediated induction of several enzymes involved
in ECM catabolism, such as heparanase and several proteinases be-
longing to the Adamts (A disintegrin and metalloproteinase with
thrombospondin motifs) family. Although FGF2 increased expression
of Adamts4 and Adamts5, which are the main proteinases responsible
for aggrecan degradation in vivo [32], WNT3a appeared to inhibit
Fig. 5. FGF2 andWNT3a alter cellular shape in RCS chondrocytes. (A) RCS chondrocyteswere treated as indicated for 72 h and photographed (dark ﬁeldwith contrast, 200x), or stained for
DNA (DAPI), focal adhesions (vinculin) and actin stress ﬁbers (phalloidin) and analyzed by immunocytochemistry (bars, 25 μm) (C, D). (B) Changes in cellular shape were quantiﬁed by
determining the cell perimeter and eccentricity (equal to 1 for perfect disc-like cells and N1 for elongated cells). The data represent measurements of 345 cells in each treatment with
indicated standard errors. Statistical differences are highlighted (ANOVA, *p b 0.001). Note the FGF2 effect on overall cell shape and actin stress ﬁber formation, which was further
enhanced by WNT3a, with elongation along a single axis observable in some cells.
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therefore be responsible for the synergistic effect of FGF2 and WNT3a
on proteoglycan ECM degradation in chondrocytes (Fig. 4). Interestingly,WNT3a signiﬁcantly enhanced the FGF2-mediated induction of expres-
sion of Adamts1,Adamts6 and Adamts7, which are all capable of degrading
aggrecan [33,34].
Table 1
Extracellularmatrix, cytoskeletal, differentiation and Rho pathway-related genes regulated by FGF2 andWNT3a signaling in RCS chondrocytes. Cells were treatedwith FGF2 (F; 10 ng/ml)
andWNT3a (W; 40 ng/ml) for 16 and 48 h and then expression proﬁlingwas carried out. The data represent the fold difference compared to untreated controls. Underlined data indicate
whenWNT3a enhanced the FGF2 effect on the given gene expression bymore than one fold (100%) relative to the control. X, conﬁrmation of gene expression by real-time RT-PCR (qPCR).
Cspg4, chondroitin sulfate proteoglycan 4; Cilp, cartilage intermediate layer protein; Chsys3, chondroitin sulfate synthase 3; Ctgf, connective tissue growth factor; Lim1, actin binding Lim
protein 1; Grinl1a, Grinl1a combined protein; B2F, B2F high sulfur protein; Ahrgap18, Rho GTPase activating protein 18; Srgap, Slit-Robo GTPase-activating protein; Fgd, FYVE, RhoGEFand
PH domain containing 3. The value is underlined when a given gene is expressed by more than one fold (100%) relative to the control.
Gene Accession no. Function F16 W16 FW16 F48 W48 FW48 qPCR
Aggrecan NM_022190 Extracellular matrix component −1.32 −1.07 −2.07 −1.62 −1.13 −11.5 X
Cspg4 NM_031022 Extracellular matrix component −6.32 −1.05 −8.30 −7.77 −1.07 −12.9 X
Lumican NM_031050 Extracellular matrix component 1.40 −2.12 2.27 4.58 −2.70 10.61 X
Chondroadherin NM_019164 Extracellular matrix component 1.00 −1.19 1.05 −2.34 −1.42 −4.00 X
Cilp NM_001108161 Extracellular matrix component −1.89 −1.65 −2.70 −2.26 −1.17 −7.15 X
Collagen 2a1 NM_012929 Extracellular matrix component −1.43 −1.20 −2.54 −2.14 −1.15 −7.88 X
Collagen 5a2 NM_053488 Extracellular matrix component 10.71 −1.38 9.65 13.92 −1.24 12.95
Collagen 9a2 NM_001108675 Extracellular matrix component −1.37 −1.07 −1.84 −2.03 −1.07 −4.37 X
Chsys3 XM_225912 Proteoglycan synthesis −3.30 −1.33 −5.22 −2.40 −1.22 −3.01 X
Heparanase NM_022605 Extracellular matrix degradation 4.55 1.09 5.98 3.66 1.07 3.44 X
Adamts1 NM_024400 Extracellular matrix degradation 1.84 −1.44 6.60 3.41 −1.34 6.22 X
Adamts4 NM_023959 Extracellular matrix degradation 2.62 −1.73 1.83 4.30 −1.95 1.56
Adamts5 NM_198761 Extracellular matrix degradation 3.98 −1.19 3.20 4.55 1.26 2.07
Adamts6 NM_001108544 Extracellular matrix degradation 3.15 −1.28 3.78 2.63 −1.37 4.14 X
Adamts7 NM_001047101 Extracellular matrix degradation 2.28 −1.19 3.21 2.47 −1.11 4.96 X
Ctgf NM_022266 Osteoinductive growth factor 5.08 2.75 7.76 4.70 3.44 4.99 X
Osteoglycin NM_001106103 Osteoinductive growth factor 3.15 1.71 3.30 5.12 5.08 10.51
Osteoactivin NM_133298 Osteoblast differentiation 6.49 1.32 6.37 4.89 1.59 5.31
S100a4 NM_012618 Calcium ion binding 27.13 −1.84 33.97 18.72 −1.05 36.67 X
Lim1 NM_001044394 Actin binding protein 3.24 −1.00 4.92 6.05 −1.11 29.42 X
Drebrin1 NM_031024 Actin binding protein 1.97 1.30 2.56 2.91 1.26 4.19 X
Grinl1a NM_001014211 Cytoskeletal structure 1.37 1.69 46.18 1.18 4.45 40.52
Keratin33b NM_001008819 Cytoskeletal structure 1.14 1.09 13.35 −1.27 3.84 6.33 X
Keratin39 NM_001004130 Cytoskeletal structure 12.09 1.59 127.0 8.88 1.65 43.16
B2F NM_001025135 Cytoskeletal structure 36.91 6.47 125.3 51.23 13.11 75.05
Protocadherin18 NM_001100524 Cell adhesion molecule 2.00 1.06 4.60 5.35 1.32 6.62 X
Protocadherin β19 XM_001056051 Cell adhesion molecule 4.99 −1.90 5.19 5.35 −1.34 13.52
Protocadherin β21 NM_001114604 Cell adhesion molecule 4.37 1.17 4.20 5.70 1.07 8.38 X
Cadherin19 NM_001009448 Cell adhesion molecule −1.27 −3.33 −4.48 −1.28 −3.22 −4.49 X
Integrin α4 NM_001107737 Cell adhesion molecule 1.36 1.07 4.99 5.08 1.76 28.68 X
Integrin α7 NM_030842 Cell adhesion molecule 2.52 1.20 3.25 1.74 1.15 4.14 X
Osteomodulin NM_031817 Cell adhesion molecule 45.40 29.0 216.3 46.74 96.30 715.6
Cdc42gap NM_001105879 Cdc42 inhibitor −3.14 −1.07 −3.25 −2.82 −1.12 −4.13 X
Ahrgap18 NM_001106354 Rho inhibitor 1.50 −1.26 2.02 2.56 −1.16 3.02
Srgap1 NM_001191784 Rho inhibitor 1.59 1.64 3.08 1.49 2.31 2.91 X
Srgap3 NM_001191975 Rho inhibitor 2.85 −1.34 9.41 3.78 −1.47 5.95 X
Fgd3 NM_001108409 Rho activator 2.71 −1.10 2.73 2.12 1.27 3.08
Fgd6 NM_001137645 Rho activator 3.43 1.00 4.77 2.23 1.03 3.42 X
RhoE NM_001007641 Small GTPase 2.17 −1.01 3.63 2.55 1.25 4.45 X
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cellular morphology (Fig. 5). FGF2 and WNT3a enhanced expression
of several genes involved in cytoskeletal remodeling (Actin binding
LIM protein1, Drebrin1), structural components of the cytoskeleton
(GRINL1A combined protein, members of the Keratin family, High sulfur
protein B2F) and cell adhesion molecules (Integrin α4, Integrin α7,
Cadherin 19, members of the Protocadherin family) (Table 1). Important-
ly, FGF2 and WNT3a also modulated expression of six genes encoding
proteins participating in signaling of the Rho family of GTPases. These
included RhoA inhibitors Arhgap18, Srgap1, Srgap3, RhoA activators
Fgd3 and Fgd6, and RhoE GTPase [35–38]. RhoA, Rac1 and Cdc2 are
prototype members of Rho family GTPases that mediate cytoskeletal
remodeling during cell adhesion, changes in cell morphology and cell
migration. Although all three proteins regulate the actin cytoskeleton,
they differ in the nature of the regulated process. While Cdc42 and
Rac1 induce lamellipodia and ﬁlopodia necessary for cell migration,
RhoA activation regulates formation of actin stress ﬁbers and subsequentFig. 6. Inhibition of the Rho pathway rescues the FGF2/WNT3a-mediated changes in RCS chondr
in thepresence of RhoApathway inhibitorsHA1100 (70 μM)andY27632 (20 μM), and analyzed
rescued the FGF2/WNT3a-mediated changes in cell shape, with no effect observed in untreated
RhoA-DN-GFP vector, then treated with FGF2 (10 ng/ml) andWNT3a (40 ng/ml) for 72 h. Expr
lular shape (GFP-positive cells), in contrast to non-transfected cells (DIC, differential contrast;changes in cell morphology [39].We did not observe increasedmigration
nor formation of lamellipodia and/or ﬁlopodia in chondrocytes treated
with FGF2 and/or WNT3a (Supplementary Movie 1), suggesting that
Cdc42 and Rac1 do not participate in changes of RCS chondrocyte mor-
phology mediated by FGF2. RhoA is required for formation of focal adhe-
sions, where components of ECM, such as ﬁbronectin, interact, via
integrins, with the actin cytoskeleton [40,41]. Interestingly, FGF2 and
WNT3a appeared to increase the amount of RCS focal cell adhesions, al-
though we did not precisely quantify this phenotype (Fig. 5C). We
previously reported a potent increase in ﬁbronectin production induced
by FGF2 of RCS chondrocytes [30].
Overall, the formation of actin stress ﬁbers, changes in cell morphol-
ogy and absence of lamellipodia or ﬁlopodia formation point toward
RhoA as the predominant Rho GTPase modulated by FGF and WNT/β-
catenin signaling in RCS chondrocytes. We tested this hypothesis by
evaluating the effect of chemical inhibition of the RhoA pathway on
the cellular shape changes mediated by FGF2 and WNT3a treatments.ocyte cellular shape. (A) Cells were treatedwith FGF2 (5 ng/ml) and/orWNT3a (40 ng/ml)
for cell shape changes 72 h later (darkﬁeldwith contrast, 200x). Both p160ROCK inhibitors
cells or cells treated with WNT3a alone. (B) RCS chondrocytes were transfected with the
ession of the dominant-negative RhoA variant rescued the FGF2/WNT3a effect on RCS cel-
DAPI, nuclear staining; Bar, 50 μm).
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Fig. 7.Model of the FGF andWNT/β-catenin signaling interaction. Activation of FGF signal-
ing promotes WNT/β-catenin signaling in chondrocytes via Erk MAP kinase-mediated
phosphorylation of WNT co-receptor Lrp6 on intracellular PPPS/TP motifs essential for
WNT/β-catenin signal transduction. The FGF andWNT/β-catenin pathways act in synergy
in regulation of gene transcription, leading to loss of extracellular matrix, changes in
cellular shape and expression of genes typical for mineralized tissues. Together, these
changes underlie changes in cell differentiation status, manifested as suppression of the
chondrocyte phenotype and partial induction of the osteoblast phenotype.
848 M. Buchtova et al. / Biochimica et Biophysica Acta 1852 (2015) 839–850The major RhoA signaling intermediate, p160ROCK kinase, was
inhibited by two unrelated chemical inhibitors, i.e., HA1100 and
Y27632 [42,43]. Both compounds rescued the RCS cellular shape change
induced by FGF2/WNT3a. No observable effect on cellular shape or
proliferation was found for either drug in FGF2-naïve cells (Fig. 6A). In
addition, transfection with dominant-negative (T19N) RhoA mutant,
C-terminally tagged with GFP did not signiﬁcantly alter the cellular
shape in control or WNT3a-treated cells but did rescue both the FGF2
and FGF2/WNT3a-mediated changes of RCS cellular shape (Figs. 6B, S3).2.4. FGF2 and WNT3a alter chondrocyte differentiation status
Compared to most tissues of mesenchymal origin, FGF signaling
triggers paradoxical changes in cartilage. It is clear that major cell phe-
notypes deﬁning the molecular pathology of FGFR3-related skeletal
dysplasia (i.e., chondrocyte growth arrest, loss of ECM and disturbed
differentiation) constitute only part of rather complex changes in
chondrocyte behavior induced by FGF signaling. Under chronic FGFR
activation, chondrocytes begin to lose their differentiated status, charac-
terized by high production of sulfated proteoglycans and collagen type
2. At the same time, mesenchymal markers, such as collagen type 1and 5, ﬁbronectin,α-smooth muscle actin and S100a4, appear together
with altered cellmorphology resemblingundifferentiatedmesenchymal
cells. Expression of genes typical formineralized tissues (Collagen type 3,
Ctgf, Osteomodulin, Osteonectin, Osteocalcin, Osteoglycin, Osteoactivin)
increases in RCS chondrocytes and several other in vitro and in vivo
chondrocyte models (Table 1) [16,30,44–52]. Collectively, this evidence
suggests that FGF signaling suppresses chondrocyte differentiation
status, while at the same time forcing the cells to express an
osteoblast-like phenotype (Fig. 7).
It is unclearwhether the abovementioned changes originate entirely
from a direct transcriptional response to FGFR3 activation or there are
other pathways involved in the process. In this respect, activation of
the RhoA pathway by FGF2 and FGF2/WNT3a might serve other roles
besides actin cytoskeletal reorganization (Fig. 5). Activation of RhoA
accompanies chondrocyte de-differentiation in vitro, whereas mesen-
chymal cells grown in alginate gel or limb micromass culture lose
RhoA expression during their chondrocytic differentiation. In addition,
chemical inhibition of the Rho pathway restores expression of cartilage
genes via upregulation of Sox9 activity, and RhoA overexpression in
ATDC5 cells delays their differentiation into hypertrophic chondrocytes
[53,54]. Consistent with these ﬁndings, the FGF2/WNT3a-mediated
suppression of hypertrophic chondrocyte differentiation observed in
all three chondrocyte models used here suggests active involvement
of RhoA in this process (Figs. 2-5). Experiments are ongoing to test
this hypothesis.
Similar to FGF, canonical WNT/β-catenin signaling regulates
several essential physiological processes in skeletogenesis. First, it
promotes osteoblast cell fate at the expense of chondrocyte cell
fate in differentiating mesenchymal osteo-chondroprogenitors [55].
Second, it accelerates terminal hypertrophic differentiation in the
mature chondrocytes of growth plate cartilage via inhibition of the
PTHrP signaling necessary for maintenance of proliferation, inhibi-
tion of Sox9 and Collagen type 2 transcription and induction ofMatrix
metalloproteinase (mmp) 13, Adamts5, Collagen type 10, Runx2 and Al-
kaline phosphatase [13,14,56]. Ectopic activation of WNT/β-catenin
signaling in murine growth plate cartilage results in neonatal lethal
dwarﬁsm characterized by a ﬂattened skull and markedly shortened
and hypoplastic long bones [57]. Limb histology revealed the virtual
absence of typical growth plate architecture, instead consisting of
undifferentiated chondrocytes with altered cell morphology and poor
expression of aggrecan, collagen type 2 and 9, and Sox9. Similarly,
isolated chick sternal chondrocytes overexpressing constitutively active
β-catenin adopted a ﬁbroblastic and ﬂat-shapedmorphology, accompa-
nied by downregulation of proteoglycan ECM via induction of Adamts5
and Mmp2, 3, 7 and 9 [57]. As many of the latter phenotypes resemble
typical features of FGFR3-related skeletal dysplasia, the evidence
presented in this article allows for speculation that activation of WNT/
β-catenin contributes to the effects of aberrant FGF signaling in
cartilage.
3. Materials and methods
3.1. Cell, micromass and limb organ cultures
Cells were propagated in DMEMmedia supplemented with 10% FBS
and antibiotics (Invitrogen, Carlsbad, CA). For growth assays, 1 × 104
cells were grown in 24-well tissue culture plates for 72 h and counted.
The growth factors and chemicals were obtained from the following
manufacturers: FGF2, WNT3a, WNT5a (R&D Systems, Minneapolis,
MN); TGFβ2 (Sigma-Aldrich, St. Louis, MO); HA1100, Y27632 (Tocris
Bioscience, Ellisville, MO). Femurs were dissected out from wild-type
mouse embryos at E17.5, and cultured in α-MEM media (Invitrogen)
supplemented with 0.2% BSA. All animal experiments were reviewed
and approved by the Institutional Animal Care and Use Committee at
CaseWestern Reserve University (protocol number 2010-0023). To ame-
liorate suffering, mice were euthanized by CO2 inhalation in accordance
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mouse embryos at E18, placed on Millipore ﬁlters above a metal mesh
and cultured in differentiating media (60% F12/40% DMEM, 10% FBS,
50 μg/ml ascorbic acid, 10 mM β-glycerol phosphate) for 8 days at
37 °C. Primary mesenchymal cultures were established from the
hindlimb bud of E12 mouse embryos. Proteolytic digestion was per-
formed using dispase II (10 U/ml; Sigma), followed by ﬁltration of the
cell suspension through a cell strainer to obtain a single-cell population.
2 × 107 cells/ml were plated in 10 μl aliquots and left to adhere for 1 h
before differentiating media was added.
3.2. Western blotting (WB) and immunocytochemistry
Cells were lysed in buffer containing 50 mM Tris–HCl pH 7.4,
150 mM NaCl, 0.5% NP-40, 1 mM EDTA and 25 mM NaF supplemented
with proteinase inhibitors. The femurs were cleaned of the soft tissues
under the preparation microscope, the growth plate cartilages were
separated from bone, and used for Western blotting. Protein samples
were resolved by SDS-PAGE, transferred onto a PVDF membrane and
visualized by chemiluminiscence (Thermo Scientiﬁc, Rockford, IL). Inte-
grated optical density (I.O.D.) of the WB signal was quantiﬁed by Scion
Image software (Scion Corporation, Frederick, MA). The following anti-
bodies were used: β-catenin (BD Biosciences, Rockville, MD); Lrp6,
pLrp6S1490 (Cell Signaling, Beverly, MA); pLrp6T1572 (Millipore, Billerica,
MA); actin (Santa Cruz Biotechnology, Santa Cruz, CA); collagen type 2
(Cedarlane Laboratories, Ontario, Canada). For immunocytochemistry,
cells were ﬁxed in 4% paraformaldehyde, stained with vinculin-FITC
(Sigma-Aldrich) antibody according to the manufacturer's protocol
andmounted in Vectashieldmedium containing DAPI (Vector Laborato-
ries, Burlingame, CA). Polymerized actinwas visualized usingAlexaFluor
594-conjugated Phalloidin (Life Technologies, Grand Island, NY).
3.3. Time-lapse and confocal microscopy, image analysis
Confocal ﬂuorescence and two photon laser scanned images were
captured on a Leica TCS-SP MP confocal microscope (Heidelberg,
Germany). Time-lapse microscopy of RCS cultures was conducted
using BioStation CT microscope (Nikon, Japan). Phase contrast images
of several cell samples were automatically acquired every 15 min for
72 h. Images were processed using VirtualDub (www.virtualdub.org)
software to increase overall contrast and sharpness, and remove
image shaking. For cellular shape analyses, 345 cells were outlined
in each treatment group and their areas were manually ﬁlled by an
unbiased scientist. The cell shape was quantiﬁed by computing two pa-
rameters, namely perimeter and eccentricity, using the DIPimage
toolbox (TU Delft, the Netherlands). The perimeter was calculated by a
chain-code method. The eccentricity was calculated as the ratio of mo-
ments of inertia of the cellular area.
3.4. Cell transfection, luciferase reporter assays, expression proﬁling and
real-time
RT-PCR cells were transfected using FuGENE6 according to the
manufacturer's protocol (Roche, Indianopolis, IN). For the luciferase
reporter assays, the μg ratio between the Fireﬂy luciferase vector
and pRL-TK (Promega,Madison,WI) control vectorwas 3:1. The lucifer-
ase activity was determined using a dual-luciferase reporter assay
(Promega). The following vectors were used: pELK1-Luc (Panomics,
Fremont, CA), pBV-SBE4-Luc [58], pGL3-E-cadherin [59], (4x48)-p89-
Luc [60], pδ51LucII-3′Gli-BS [61], pNF-κB-Luc (Agilent Technologie,
Santa Clara, CA) and Topﬂash (obtained from R. Moon). The vector
expressing dominant-negative RhoA (pcDNA3-EGFP-RhoA-T19N) was
obtained from Addgene (Cambridge, MA). For microarray analysis,
total RNA was isolated using the RNeasy mini kit and cleaned with a
RNeasy spin column (Qiagen, Valencia, CA). All reagents and equipment
used for the subsequent analyses were from Affymetrix (Santa Clara,CA). cDNA was synthesized using the GeneChip WT cDNA synthesis
kit and random hexamers tagged with a T7 promoter sequence.
Single-stranded cDNA was hybridized to probe sets present on a
GeneChip rat gene 1.0 ST array, offeringwhole genome transcript cover-
age. Two to three independent biological samples were analyzed for
each treatment and the control. The intensity ﬁles were produced
using GeneChip Operating Software v1.4 and analyzed with Expression
Console software v1.1. using the PLIER algorithm. For real-time RT-PCR,
total RNAwas isolated using the RNeasymini kit (Qiagen) and poly-dT-
primed cDNA was synthesized from 3 μg of RNA using a Omniscript RT
kit (Qiagen). Real-time RT-PCRs were carried out using Dynamo qPCR
chemistry (Finnzymes, Espoo, Finland), with pre-designed gene-
speciﬁc primers obtained from Qiagen.
3.5. Histological stains, [35S]sulfate labeling and in situ hybridization
For quantiﬁcation of ECM production, cells were grown in the pres-
ence of 10 μCi/ml of [35S]sulfate (Perkin Elmer, Boston,MA) for 72 h, and
the incorporated radioactivity was determined by liquid scintillation.
For alcian blue and alizarin red staining, micromass cultures were
ﬁxed in paraformaldehyde, stained with 0.5% alcian blue in HCl or 2%
alizarin red in distilled water overnight, and photographed with
a Leica S6D microscope. Tibias were ﬁxed in paraformaldehyde,
decalciﬁed in EDTA, embedded in parafﬁn and sectioned at the thick-
ness of 5 μm. Alternative slides were stained by hematoxylin–eosin for
morphological analysis. For in situ hybridization, plasmid Col10a1
(IMAGp998B1114092Q, Biovalley) was linearized by PCR reaction
with M13 primers. Sense and antisence DIG labeled riboprobes were
produced by SP6 and T7 RNA polymerase, respectively. Hybridization
was performed at 60 °C overnight. Sense DIG labeled probe was used
as negative control. Slides were counterstained with eosin.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.12.020.
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